A large deletion in TSC2 causes tuberous sclerosis complex by dysregulating PI3K/AKT/mTOR signaling pathway

被引:4
|
作者
Fu, Jiahui [1 ]
Liang, Peili [2 ]
Zheng, Yingchun [3 ]
Xu, Cailing [1 ]
Xiong, Fu [3 ]
Yang, Fang [1 ]
机构
[1] Southern Med Univ, Zhujiang Hosp, Dept Fetal Med & Prenatal Diag, Guangzhou, Peoples R China
[2] Longgang Dist Matern & Child Healthcare Hosp Shenz, Outpatient & Emergency Management Off, Shenzhen, Peoples R China
[3] Southern Med Univ, Sch Basic Med Sci, Dept Med Genet, Guangzhou, Peoples R China
关键词
Tuberous sclerosis complex; TSC2; Large deletion; PAM signaling pathway; Cardiac rhabdomyoma; Hypomelanotic macules; BRAIN;
D O I
10.1016/j.gene.2024.148312
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background/aim: Tuberous sclerosis complex (TSC) is a multi-system syndrome caused by loss-of-function mutation in TSC1 or TSC2. Most TSC patients present with cardiac rhabdomyoma or cortical tubers during fetal life, and the symptoms are not uniform as their age. The gene products of TSC1/2 are components of the TSC protein complex and are important role in the PI3K/AKT/mTOR (PAM) signaling pathway. Based on three members of a family with variable expressivity, the purpose of this study was to clarify the clinical features of TSC in different age groups and to analyze the genetic characteristics of TSC2 gene. Methods: Clinical exome sequencing and co-segregation were used to identify a three-generation family with four affected individuals. HEK-293T cell model was constructed for subsequent experiments. Quantitative RT-PCR, western blotting, and subcellular localization were used to analyze the expression effect of TSC2 mutation. CCK-8 assay, wound healing assay, and cell cycle analysis were used to analyze the function effect of TSC2 mutation. Result: We identified a TSC family with heterozygous deletion of exon 4 in TSC2 by clinical exon sequencing. Sanger sequencing indicated that the affected individuals have 2541-bp deletion that encompassed exon 4 and adjacent introns. Deletion of exon 4 decreased the TSC2 mRNA and protein levels in HEK-293T cells, and activated the PI3K/AKT/mTOR pathway, thereby altering the cell cycle and promoting cell proliferation and migration. Conclusion: We confirmed the pathogenicity of the large deletion in TSC2 in a three- generations family.. Deletion of exon 4 of TSC2 affected cell proliferation, migration, and cell cycle via abnormal activation of the PAM pathway. This study evaluated the pathogenic effect of deletion of exon 4 of TSC2 and investigated the underlying mechanism.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] A large deletion in TSC2 causes tuberous sclerosis complex by dysregulating PI3K_AKT_mTOR signaling pathway (vol 909, 148312, 2024)
    Fu, Jiahui
    Liang, Peili
    Zheng, Yingchun
    Xu, Cailing
    Xiong, Fu
    Yang, Fang
    GENE, 2024, 919
  • [2] Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway
    Presneau, N.
    Shalaby, A.
    Idowu, B.
    Gikas, P.
    Cannon, S. R.
    Gout, I.
    Diss, T.
    Tirabosco, R.
    Flanagan, A. M.
    BRITISH JOURNAL OF CANCER, 2009, 100 (09) : 1406 - 1414
  • [3] Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway
    N Presneau
    A Shalaby
    B Idowu
    P Gikas
    S R Cannon
    I Gout
    T Diss
    R Tirabosco
    A M Flanagan
    British Journal of Cancer, 2009, 100 : 1406 - 1414
  • [4] The PI3K/Akt/mTOR signaling pathway
    Dennis, P. A.
    ANNALS OF ONCOLOGY, 2011, 22 : 19 - 19
  • [5] RAS Signaling in the PI3K/AKT/MTOR Pathway
    Nussinov, Ruth
    Zhang, Mingzhen
    Jang, Hyunbum
    BIOPHYSICAL JOURNAL, 2020, 118 (03) : 51A - 51A
  • [6] Design, synthesis and molecular docking of novel substituted azepines as inhibitors of PI3K/Akt/TSC2/mTOR signaling pathway in colorectal carcinoma
    Noser, Ahmed A.
    Abdelmonsef, Aboubakr H.
    Salem, Maha M.
    BIOORGANIC CHEMISTRY, 2023, 131
  • [7] Evaluation of the PI3K/AKT/mTOR pathway in multiple sclerosis
    Mammana, Santa
    Fagone, Paolo
    Cavalli, Eugenio
    Basile, Maria Sofia
    Petralia, Maria Cristina
    Nicoletti, Ferdinando
    Mangano, Katia
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2017, 40 : S51 - S51
  • [8] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [9] Stability Analysis of the PI3K–Akt–mTOR Signaling Pathway
    Sapega T.S.
    Guria G.T.
    Biophysics, 2020, 65 (2) : 259 - 267
  • [10] AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
    Bhatt, Aadra P.
    Damania, Blossom
    FRONTIERS IN IMMUNOLOGY, 2013, 3